Together with Briya a leading top 10 pharma company conducted research focused on metastatic non-small cell lung cancer (NSCLC) in patients with wild-type characteristics. Specifically, the study focuses on determining the average time elapsed from diagnosis, both pathological and molecular, to the commencement of treatment, as well as evaluating the average number of biopsies conducted within this patient population. Additionally, the research endeavors to analyze the mortality rate among individuals diagnosed with stage 4 metastatic disease.